The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Quest Diagnostics, Inc (NYSE: DGX) was $179.33 for the day, down -0.90% from the previous closing price of $180.96. In other words, the price has decreased by -$0.90 from its previous closing price. On the day, 1.4 million shares were traded. DGX stock price reached its highest trading level at $180.675 during the session, while it also had its lowest trading level at $178.25.
Ratios:
Our analysis of DGX’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 62.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.38. For the most recent quarter (mrq), Quick Ratio is recorded 0.99 and its Current Ratio is at 1.09. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.79.
On April 02, 2025, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $195.
Citigroup Downgraded its Buy to Neutral on March 04, 2025, while the target price for the stock was maintained at $185.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 26 ’25 when PREVOZNIK MICHAEL E sold 227 shares for $188.13 per share. The transaction valued at 42,706 led to the insider holds 38,117 shares of the business.
PREVOZNIK MICHAEL E bought 227 shares of DGX for $42,706 on Sep 26 ’25. On Sep 23 ’25, another insider, PREVOZNIK MICHAEL E, who serves as the SVP & General Counsel of the company, sold 28,288 shares for $187.12 each. As a result, the insider received 5,293,313 and left with 38,117 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DGX now has a Market Capitalization of 20053297152 and an Enterprise Value of 26236297216. As of this moment, Quest’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.44, and their Forward P/E ratio for the next fiscal year is 17.39. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.91 while its Price-to-Book (P/B) ratio in mrq is 2.78. Its current Enterprise Value per Revenue stands at 2.493 whereas that against EBITDA is 12.748.
Stock Price History:
The Beta on a monthly basis for DGX is 0.59, which has changed by 0.22076237 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, DGX has reached a high of $191.49, while it has fallen to a 52-week low of $146.17. The 50-Day Moving Average of the stock is -0.19%, while the 200-Day Moving Average is calculated to be 4.86%.
Shares Statistics:
DGX traded an average of 977.58K shares per day over the past three months and 922270 shares per day over the past ten days. A total of 112.00M shares are outstanding, with a floating share count of 111.28M. Insiders hold about 0.49% of the company’s shares, while institutions hold 98.10% stake in the company. Shares short for DGX as of 1757894400 were 4421542 with a Short Ratio of 4.52, compared to 1755216000 on 4031308. Therefore, it implies a Short% of Shares Outstanding of 4421542 and a Short% of Float of 4.5100003.
Dividends & Splits
With its trailing 12-month dividend rate of 3.1, DGX has a forward annual dividend rate of 3.15. Against a Trailing Annual Dividend Yield of 0.017206926. The stock’s 5-year Average Dividend Yield is 1.86. The current Payout Ratio is 39.15% for DGX, which recently paid a dividend on 2025-10-03 with an ex-dividend date of 2025-10-03. Stock splits for the company last occurred on 2005-06-21 when the company split stock in a 2:1 ratio.
Earnings Estimates
The stock of Quest Diagnostics, Inc (DGX) is currently being evaluated by 14.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $2.42, with high estimates of $2.5 and low estimates of $2.35.
Analysts are recommending an EPS of between $9.81 and $9.67 for the fiscal current year, implying an average EPS of $9.75. EPS for the following year is $10.32, with 17.0 analysts recommending between $10.69 and $9.8.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 12 analysts. It ranges from a high estimate of $2.76B to a low estimate of $2.71B. As of. The current estimate, Quest Diagnostics, Inc’s year-ago sales were $2.49BFor the next quarter, 12 analysts are estimating revenue of $2.72B. There is a high estimate of $2.74B for the next quarter, whereas the lowest estimate is $2.69B.
A total of 16 analysts have provided revenue estimates for DGX’s current fiscal year. The highest revenue estimate was $10.93B, while the lowest revenue estimate was $10.82B, resulting in an average revenue estimate of $10.86B. In the same quarter a year ago, actual revenue was $9.87BBased on 16 analysts’ estimates, the company’s revenue will be $11.24B in the next fiscal year. The high estimate is $11.38B and the low estimate is $11.12B.
